| |
Educational Slide Kits available to review and download
|
|
More abstracts in the Elsevier medical abstract database on Embase.com. |
|
|
Thromboprophylaxis in Patients With Atrial Fibrillation or a Mechanical Heart Valve Undergoing Elective Surgery
|
Alex C. Spyropoulos, MD, FACP, FCCP
Patients with atrial fibrillation, mechanical prosthetic heart valves, and other conditions are commonly treated with a vitamin K antagonist (VKA) to reduce the risk of stroke. When these patients must undergo surgery, the physician is faced with a dilemma: continuing VKA therapy increases the bleeding risk, whereas discontinuing it increases stroke risk. Bridging therapy is the use of an alternative anticoagulant agent in the perioperative period designed to reduce the risk of stroke without substantially increasing bleeding. This slide kit, created by Alex C. Spyropoulos, MD, FACP, covers important issues related to bridging therapy and examines the results of recent trials of bridging therapy with a variety of agents. |
|
|
View this lecture »
|
Recent Clinical Trials in High-risk ST-Segment Elevation Myocardial Infarction (STEMI) Patients: Focus on PCI
|
C. Michael Gibson, MS, MD, FACC
This slide kit presents data from recent clinical trials, including ExTRACT-TIMI (Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis in Myocardial Infarction) 25 and other studies, on the use of antithrombotic therapy in high risk ST elevation myocardial infarction (STEMI) patients. Patient populations assessed include those with advanced age, diabetes, or reduced renal function, as well as in those undergoing percutaneous coronary intervention. This slide kit includes evidence on the benefit of reducing the dosage of antithrombotic agents in high-risk patients. |
|
|
View this lecture »
|
Optimizing Door-To-Treatment Times in STEMI: A Community Hospital Approach
|
Christopher Cannon, MD
Welcome to Optimizing Door-to-Treatment Times in STEMI, an On-Demand CME activity. The objective of this program is to help community hospital teams improve their door-to-treatment times and adhere to best practices in the management of patients with ST elevation myocardial infarction (STEMI). Data from several studies, registries, and quality improvement programs show that keeping door-to-needle times within 30 minutes (“Code 30”) or door-to-balloon times within 90 minutes (“Code 90”) translates into better patient outcomes. New studies also demonstrate improved outcomes through the use of adjunctive antithrombotic therapy with fibrinolysis. A challenging case study will be followed throughout the lecture, with opportunities to reflect on clinical decision-making at several points in the patient’s treatment path in light of the latest study results and guidelines. |
|
|
View this lecture »
|
Antithrombotic Therapy in the Management of Acute Coronary Syndromes - Downloadable Slide Kit
|
The following slide presentation provides a basic overview of current treatment recommendations for cardiologists, interventional cardiologists, and other critical care specialists who treat patients with acute coronary events, including interpretation and implementation of the latest guidelines on the use of antithrombotic drugs in patients with ACS. The current American College of Cardiology/American Heart Association (ACC/AHA) treatment algorithms for ACS are described as well as recent trial data that may impact on those treatment algorithms. |
|
|
View this lecture »
|
Thromboprophylaxis: Identifying Patients At Risk for VTE
|
Arthur P. Wheeler, MD
The following slide presentation provides information for identifying at-risk patients who require prophylaxis for the prevention of venous thromboembolism (VTE) in the medical setting. |
|
|
View this lecture »
|
Prevention of venous thromboembolism following surgery - Downloadable Slide Kit
|
The following slide presentation discusses the risk of venous thromboembolism (VTE) among patients undergoing surgical procedures, the surgical procedures that are associated with the highest risk of VTE, and how surgical patients can be protected against VTE. |
|
|
View this lecture »
|
|